RxDoctor Payments Data

Amber Syed, MD

Internal Medicine · Atlanta, GANPI 1225280795

Payments from drug & device makers

$2,300in general payments, 2019–2025

Across 129 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$590
  • Lilly USA, LLC$327
  • Amgen$157
  • AstraZeneca$145
  • GSK$143
  • AbbVie$120
  • plus $818 from 15 others

What the payments were for

  • Food & beverage$2,300100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,300 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$38,362
Medicare patients
96
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin96$121,625
OzempicSemaglutide78$107,621
JanuviaSitagliptin Phosphate46$68,989
MounjaroTirzepatide21$30,350
Synjardy XrEmpagliflozin/Metformin Hcl21$28,931
EliquisApixaban18$28,480
TrulicityDulaglutide12$24,543
JanumetSitagliptin Phos/Metformin Hcl24$24,383
ProliaDenosumab13$21,695
FarxigaDapagliflozin Propanediol12$19,518
XareltoRivaroxaban12$17,073
LinzessLinaclotide17$16,301
TradjentaLinagliptin12$13,014
Gabapentin152$2,945
Ibandronate Sodium68$2,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$50$163,569129 claims
Novo NordiskOzempic$590$107,62178 claims
Lilly USA, LLCMounjaro, Trulicity$327$54,89333 claims
AmgenProlia$157$21,69513 claims
AstraZenecaFarxiga$145$19,51812 claims
AbbVieLinzess$120$16,30117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →